Kymera Therapeutics Inc. announced its strategic plans for 2026, focusing on advancing its oral immunology pipeline. The company intends to initiate a Phase 1 clinical trial for KT-579 in healthy volunteers in the first quarter of 2026, with data expected in the second half of the year. Kymera also plans to advance at least one new development candidate towards an Investigational New Drug $(IND)$ application for a first-in-class, oral immunology program in 2026. Ongoing clinical trials include the KT-621 BROADEN2 Phase 2b trial in atopic dermatitis, with data anticipated by mid-2027, and the KT-621 BREADTH Phase 2b trial in asthma, with results expected in late 2027. The company reports a strong cash position, with a financial runway projected into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011104), on January 13, 2026, and is solely responsible for the information contained therein.